The Annual General Meeting re-elected Bo Jesper Hansen (Chairman), Vlad Artamonov, Charlotte Edenius, Hans Wigzell and Klaus Wilgenbus. Rune Fransson and Per-Olof Edin declined re-election.
"We are pleased to welcome three new board members, whose diverse experiences and areas of competence will be extremely valuable as we work to create a long term profitable business based on world-leading research. I would also like to extend my sincere thanks and appreciation to the outgoing members Rune Fransson and Per-Olof Edin, who during their time on the board have made significant contributions to the company's development", said Bo Jesper Hansen, Chairman of Karolinska Development.
Facts about the newly elected Board Directors
Robert Holland Born in 1955. M.D., Ph.D. Board director of Newron Pharmaceuticals SpA and Early Clinical Development Consulting Ltd. Medical Director and part of senior management at Oxford Gene Technology IP Ltd. Previous assignments: Leading position in AstraZeneca, including Head of Personalized Healthcare & Biomarkers and Head of Neuroscience. Positions in clinical research at Wellcome, Solvay and Upjohn. Fellow of the Faculty of Pharmaceutical Medicine.
Henrijette Richter Born in 1971. Ph.D., M. Sc. Other assignments: Investment Director at Novo Seeds, Novo A/S. Chairman of Avilex Pharma ApS and Affinicon ApS, Board member at Orphazyme A/S and EpiTherapeutics A/S, and the Green Development and Demonstration Programme (GUDP) of the Danish Food, Agriculture and Fisheries Ministry. Previous assignments: Chairman of Cytoguide ApS, Board member at MycoTeq ApS and Nanoference ApS. Member of the Advisory Board at the Institute for Systems Biology, Technical University of Denmark.
Carl Johan Sundberg Born in 1958. M.D., Ph.D., Professor of physiology. Other positions: Board Director of Cobra Biologics AB, Coordinator Science and Society, the Vice-Chancellor's Office at KI, director of the Unit of Bioentrepreneurship, Fellow of the Royal Swedish Academy of Engineering Sciences, member of the Medical Commission of the International Olympic Committee, Inspector General of the Medical Association and Chairman of Research!Sweden. Previous assignments: Investment Director at Karolinska Investment Fund, Board Director of Global Genomics AB, AngioGenetics AB, NsGene AS, Cellectricon AB, Alfta Rehab Center Holding AB, Karolinska Education AB and Feelgood Swedish AB, Vice President of Euroscience and Chairman of the Swedish Professional Associations for Physical Activity and Sports Medicine.
For further information, please contact: Bo Jesper Hansen, Chairman, Karolinska Development AB Phone: +45 (0)26 12 83 84, e-mail: bo.jesper.hansen@karolinskadevelopment.com
Benjamin Nordin, IRO, Karolinska Development AB Phone: +46 (0)73 093 60 80, e-mail: benjamin.nordin@karolinskadevelopment.com
TO THE EDITORS About Karolinska Development AB Karolinska Development aims to create value for patients, researchers, investors and society by developing innovations from world class science into differentiated products that can be partnered. The business model is to: SELECT the most commercially attractive medical innovations that can potentially satisfy unmet medical needs; DEVELOP innovations to the stage where the greatest return on investment can be achieved; and COMMERCIALIZE the innovations through the sale of companies or out-licensing of products. An exclusive deal flow agreement with Karolinska Institutet Innovations AB, along with other cooperation agreements with leading universities, delivers a continuous flow of innovations. Today, the portfolio consists of 34 projects, of which 17 are in clinical development. For more information, please visit www.karolinskadevelopment.com.
